( ersen sodium) Injection is theCompany'...)Genta Incorporated to Present Multiple Abstracts at the Annual,Meeting of the American Society of Clinical Oncology,Health

ersen sodium) Injection is the Company's lead compound from its oligonucleotide program. The lead drug in Genta's small molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in the U.S. for treatment of symptomatic patients with cancer related hypercalcemia that is resistant to hydration. Genta is partnered with IDIS (www.idispharma.com) on a program whereby both Ganite(R) and Genasense(R) are available on a "named- patient" basis in countries outside the United States. For more information about Genta, please visit our website at: www.genta.com.

Safe Harbor

This press release may contain forward-looking statements with respect to business conducted by Genta Incorporated. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Forward- looking statements include, without limitation, statements about:

    -- the Company's ability to obtain necessary regulatory approval for

       Genasense(R) from the U.S. Food and Drug Administration ("FDA") or

       European Medicines Agency ("EMEA");

    -- the safety and efficacy of the Company's products or product

       candidates;

    -- the Company's assessment of its clinical trials;

    -- the commencement and completion of clinical trials;

    -- the Company's ability to develop, manufacture, license and sell its

       products or product candidates;

    -- the Company's ability to enter into and successfully execute license

       and collaborative agreements, if any;

    -- the adequacy of the Company's capital resources and cash flow

       projections, and the Company's ability to obtain sufficient financing

       to maintain the Company's planned operations;

    -- the adequacy of the Company's paten
'"/>




Page: 1 2 3 
Related medicine technology :

1. Genta Announces Results of Phase 1 Study Using Genasense
Administered by Intermittent Subcutaneous Injection
2. The Past, Present and Future of HLA Typing
3. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral
Anticoagulant, Presented Today at the XXIst Congress of the
International Society on Thrombosis and Haemostasis
4. Neose Announces Presentation of Positive Preclinical Data on
GlycoPEGylated Factor VIIa at the XXI Congress of the International
Society on Thrombosis and Haemostasis
5. Inspiration Biopharmaceuticals Presents Data From Hemophilia
Program at International Society On Thrombosis and Haemostasis
(ISTH) Annual Meeting
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule
Therapeutic Clinical Trial Results Presented at the 34th Annual
Meeting of the Controlled Release Society
7. Generex Biotechnology to Make Presentations At 46th Annual Meeting
of the European Society of Pediatric Endocrinology
8. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging
Growth Opportunities Conference
9. ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth
Opportunities Conference
10. Accelrys to Present to Investors at C.E. Unterberg Emerging Growth
Opportunities Conference
11. Metabasis to Present at C.E. Unterberg, Towbin Emerging Growth
Conference and Attend Pacific Growth Equities Conference